Healthcare | November 08, 2022
Phase III trial also demonstrated a statistically significant reduction (14%) in hospitalization for any cause, bringing potential relief for patients and reducing burden on healthcare systems
The participants discussed the latest developments under ABDM that shall enable true interoperability in the health sector and how effective adoption of ABDM can pave the way towards Universal Health Coverage
Gland Pharma Q2 FY2023 consolidated net profit up at Rs. 241.24 Cr
Separate Phase 3 study evaluating 200 days of therapy with PREVYMIS in HSCT recipients at high risk of late clinically significant CMV infection recently completed, meeting its primary endpoint
The TBDA is a collaboration established among biopharmaceutical companies, research organizations and universities to accelerate the discovery and development of novel therapeutic candidates against TB.
He is a seasoned business leader with a successful track record of over 26 years across local and area roles within the pharmaceutical industry
CHMP positive opinion is based on evidence from the EFFISAYIL trial, the largest clinical trial in
The symposium was organized to provide an opportunity to highlight the advances of aortic surgery and to discuss the future of aortic aneurysm management.
Subscribe To Our Newsletter & Stay Updated
